• Rodrigo Cartin-Ceba, Rolf D Hubmayr, Rui Qin, Steve Peters, Rogier M Determann, Marcus J Schultz, and Ognjen Gajic.
• Department of Medicine, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN. Electronic address: cartinceba.rodrigo@mayo.edu.
• J Crit Care. 2015 Feb 1;30(1):219.e1-7.

PurposeTo evaluate the predictive value of 6 different biomarkers in the development of multiple-organ failure (MOF) and mortality in a contemporary prospective cohort of acute respiratory distress syndrome (ARDS).MethodsPatients with ARDS admitted to a tertiary referral center during an 8-month period were included. Plasma sample collection of 6 different biomarkers on days 1, 3, and 5 after ARDS onset was performed (von Willebrand factor, thrombin-antithrombin III complex, plasminogen activator inhibitor 1, interleukin 8, receptor for advanced glycation end-products, and club cell secretory protein). Main outcomes included hospital mortality and development of MOF. Logistic regression models for MOF and mortality prediction were created including biomarkers levels and clinical predictors.ResultsOne hundred patients were included in the study. Do-not-resuscitate status and McCabe score were independently associated with increased mortality. None of the 6 biomarkers measured at the time of ARDS diagnosis predicted hospital mortality. After adjustment for important clinical characteristics, elevated day-1 interleukin 8 levels were associated with the development of MOF.ConclusionsAddition of biomarkers did not improve mortality prediction in this cohort of ARDS. Association between elevated interleukin 8 levels and progression of organ failures suggests an important role of exaggerated inflammatory response in the development of MOF.Copyright © 2014 Elsevier Inc. All rights reserved.

36 keywords...

hide…